
Cluster for Individualized Immune Intervention (Ci3)
Cluster für Individualisierte ImmunIntervention
Overview
About us
The Cluster for Individualized Immune Intervention (Ci3) promotes the development of innovative immunotherapies and diagnostics for serious diseases with an unmet medical need. Its strong network of pharmaceutical and biotechnology companies, universities, and other research institutions is located in the Rhine-Main area, a region with one of Europe’s longest and most successful histories in pharmaceutical innovations. Through the cluster's combined expertise and international collaborations, Ci3 aims to advance personalized medicine by breaking down innovation barriers and enabling disruptive technologies.
Established - 24 July 2010
Staff in the management team - 1-5
Cluster composition
-
92Cluster Members
-
48SME's
-
21Large Companies
-
23Research Organisations, Universities, Technology Centers
- Setting up of an innovative network of partners working in the field of immunoncology, infectious and autoimmune diseases, in particular individualized cancer immunotherapies. Successful implementation of new therapeutic concepts into clinic.
- Development of innovative bioinformatics tools for individualized and personalized medical approaches.
- Connecting SME and research institution with large pharmaceutical companies, translating innovative technologies from basic research into the clinic.
Legal form of the cluster organisation
Languages spoken
Link to the team description on the cluster organisation website
Other label
Management team
Sectorial and industrial focus
Sectoral industries
Sectoral Industries (NACE 4 digit)
Cross-sectoral industries
Industrial Alliances and Ecosystems
Technology fields
S3 EU priority areas
Services
Support services provided
Support programmes
EU Programmes
Name & description
Project name
Project 1. Permides: It is the aim of PERMIDES to strengthen the competitiveness and foster the innovation potential of personalized medicine as an emerging industry in Europe by providing key solutions for the reconfiguration of the biopharmaceutical value chain towards a Health Economy 4.0 with a special focus on oncology (i.e. cancer treatment). Current value chain challenges lie in e.g. data gathering and exchange, big data and machine learning, or new software-based marketing methods. Via a cross-clustering approach, leading biopharma and IT clusters from three countries (Austria, Germany, and Norway) will create novel cross-sectoral collaborations between SMEs to address innovation barriers in the biopharma sector via cutting-edge IT solutions. As a cross-cutting industry, the ICT and software sector is an enabler of innovation in many industries and therefore provides a broad knowledge base of processes and best practice solutions in diverse industrial contexts and business environments.
Project 2. Digi-B-Cube (Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries) The DIGI-B-CUBE project aims to unlock the cross-sectoral collaborative potential of SMEs by combining artificial intelligence (AI) and cognitive computing digital technologies (CCDT) with the bioimaging-biosensing-biobanking (B-CUBE) industries to deliver market sensitive disruptive technologies, and by generating innovative solutions that enhance patient-centred diagnostic work-flows, delivered through the improved algorithms for the efficiency and accuracy of medical diagnostics. DIGI-B-CUBE will study the characteristics in market dynamics & specificities for innovations created by merging AI, CCDT & B-CUBE industries. By providing a framework for a more structured cross-sectoral and cross-border collaboration that manages all of the complex workflows within the process, DIGI-B- CUBE instantiates the mechanisms to ensure long-term sustainability of the action through collaborations of the participating clusters with hospitals, academia, industry, investors, business angels, managing authorities of the national innovation agencies, and the European Commission support measures (such as EIT, ESIF). The main objective of this project is to provide key digital solutions for the reconfiguration of the medical diagnostics value chain towards a Health Economy 4.0 with a special focus on the biobanking, bioimaging and biosensing industries. Activities financed by the ESIF in the participating regions as part of the Smart Specialisation Strategies will be bundled in cooperation with the responsible managing authorities in addition to the innovation voucher scheme for SMEs. By integrating innovations in IT into bioimaging, biosensing and biobanking industries, this project will accelerate the goal of personalised medicine that can eventually offer patients a fast and efficient diagnosis-treatment-healthcare system.
Cooperation activities
International cooperation
Targeted countries
Transnational cooperation
Targeted countries
Transnational support activites
- none -International support activites
Promotional ActivitiesUpcoming events
Monday | Tuesday | Wednesday | Thursday | Friday | Saturday | Sunday |
---|---|---|---|---|---|---|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|
1
|
2
|
3
|
4
|
|
|
|
|
Latest news and documents
There is no uploaded content...
Submitted best practices
There is no uploaded content...